| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 04/12/2001 | WO2001025398A2 Process for inducing functional tolerance to gene transfer products |
| 04/12/2001 | WO2001025269A2 Human g-protein coupled receptor |
| 04/12/2001 | WO2001025257A2 Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery |
| 04/12/2001 | WO2001025252A1 Tissue plasminogen activator-like protease |
| 04/12/2001 | WO2001024824A1 Rhodamine derivatives for photodynamic diagnosis and treatment |
| 04/12/2001 | WO2001024823A1 Cd40 antagonist for treating psoriasis |
| 04/12/2001 | WO2001024782A2 Pharmaceutical agent for the treatment of cachexia and/or cardiogenic shock |
| 04/12/2001 | WO2001024774A1 Ortho ester lipids |
| 04/12/2001 | WO2001024772A1 Formulation for menopausal women |
| 04/12/2001 | WO2000061755A3 Secreted human proteins |
| 04/12/2001 | DE19948126A1 Pharmazeutisches Mittel zur Behandlung von Kachexie und/oder kardiogenem Schock A pharmaceutical composition for the treatment of cachexia and / or cardiogenic shock |
| 04/12/2001 | CA2699662A1 Rhodamine derivatives for photodynamic diagnosis, prevention and treatment of immunologic disorders |
| 04/12/2001 | CA2645397A1 Formulation for menopausal women |
| 04/12/2001 | CA2388864A1 Ortho ester lipids |
| 04/12/2001 | CA2388487A1 Tissue plasminogen activator-like protease |
| 04/12/2001 | CA2385045A1 Ifn-alpha homologues |
| 04/12/2001 | CA2379462A1 Human g-protein coupled receptor |
| 04/11/2001 | EP1090917A1 Quinolin-4-yl derivatives and their use as NMDA-receptor subtype blockers |
| 04/11/2001 | EP1090122A1 Nucleic sequence and deduced protein sequence family with human endogenous retroviral motifs, and their uses |
| 04/11/2001 | EP1090105A1 Ependymal neural stem cells and method for their isolation |
| 04/11/2001 | EP1090003A1 7-alkyl- and cycloalkyl-substituted imidazotriazinones |
| 04/11/2001 | EP1089724A1 Therapeutic compositions and methods of use |
| 04/11/2001 | EP0866704B1 Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis |
| 04/11/2001 | CN1290698A Quinoline-4-base deviative I |
| 04/11/2001 | CN1064248C Medicinal powder for curing facial paralysis |
| 04/10/2001 | US6214870 Antiarthritic agents; anticancer agents |
| 04/10/2001 | US6214856 Treating neurodegenerative disorders, e.g., alzheimer's disease, strokes, traumatic brain injury; antiischemic agents; muscular dystrophy; also cataracts; platelet aggregation |
| 04/10/2001 | US6214844 Substituted imidazole compounds |
| 04/05/2001 | WO2001023584A1 Human ubiquitin protease |
| 04/05/2001 | WO2001023546A1 37 human secreted proteins |
| 04/05/2001 | WO2001023424A1 A phosphatidylethanolamine binding protein (pebp-2) and uses thereof |
| 04/05/2001 | WO2001023408A1 5-hydroxysapogenin derivatives with anti-dementia activity |
| 04/05/2001 | WO2001023407A1 Sapogenin derivatives and their use in the treatment of cognitive dysfunction |
| 04/05/2001 | WO2001023406A1 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia |
| 04/05/2001 | WO2001023402A1 43 human secreted proteins |
| 04/05/2001 | WO2001023399A1 Compounds for the treatment of ischemia |
| 04/05/2001 | WO2001023359A1 Aryl-sulfonamide substituted benzimidazol derivatives and use of said as tryptase inhibitors |
| 04/05/2001 | WO2001022987A1 Trail: an inhibitor of autoimmune inflammation and cell cycle progression |
| 04/05/2001 | WO2001006015A8 NOVEL GLYCOSYL SULFOTRANSFERASES GST-4α, GST-4β, AND GST-6 |
| 04/05/2001 | WO2000073450A3 Cytoskeleton-associated proteins |
| 04/05/2001 | WO2000073334A3 Human sorting nexins |
| 04/05/2001 | WO2000065027A3 Human gil-19/ae289 proteins and polynucleotides encoding same |
| 04/05/2001 | WO2000057877A8 Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof |
| 04/05/2001 | WO2000056891A3 Human transmembrane proteins |
| 04/05/2001 | WO2000044362A3 The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation |
| 04/05/2001 | CA2640998A1 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia |
| 04/05/2001 | CA2386079A1 Compounds for the treatment of ischemia |
| 04/05/2001 | CA2386002A1 Trail: an inhibitor of autoimmune inflammation and cell cycle progression |
| 04/05/2001 | CA2385169A1 43 human secreted proteins |
| 04/05/2001 | CA2384659A1 37 human secreted proteins |
| 04/05/2001 | CA2382892A1 Substituted benzimidazol derivatives, processes for preparing them and their use as pharmaceutical compositions |
| 04/04/2001 | EP1087937A1 Cyclic hydroxamic acids as metalloproteinase inhibitors |
| 04/04/2001 | EP1087934A1 Aminocyclohexyl ether compounds and uses thereof |
| 04/03/2001 | US6211368 Hydrolysis of corresponding ester |
| 04/03/2001 | US6211201 Multivalent salts of pyridostigmine and related compounds |
| 04/01/2001 | CA2321324A1 Quinolin-4yl derivatives |
| 03/29/2001 | WO2001021812A1 Phosphatases which activate map kinase pathways |
| 03/29/2001 | WO2001021660A1 Peptides for combating the autoantibodies that are responsible for dilatative cardiomyopathy (dcm) |
| 03/29/2001 | WO2001021658A1 32 human secreted proteins |
| 03/29/2001 | WO2001021628A1 A substantially cell membrane impermeable compound and use thereof |
| 03/29/2001 | WO2001021204A1 Therapeutic uses of m3 polypeptide |
| 03/29/2001 | WO2001021186A1 Compositions inhibiting muscle atrophy |
| 03/29/2001 | WO2001021156A1 Pharmaceutical chewing gum formulations |
| 03/29/2001 | WO2001020969A2 Use of ribose to prevent cramping and soreness in muscles |
| 03/29/2001 | WO2000075139A3 Benzothiazinone and benzoxazinone compounds |
| 03/29/2001 | DE19945810A1 Substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Substituted benzimidazole derivatives, processes for their preparation and their use as medicaments |
| 03/29/2001 | CA2385552A1 Phosphatases which activate map kinase pathways |
| 03/29/2001 | CA2385480A1 32 human secreted proteins |
| 03/29/2001 | CA2383598A1 Therapeutic uses of m3 polypeptide |
| 03/29/2001 | CA2369515A1 Pharmaceutical chewing gum formulations |
| 03/28/2001 | EP1086097A1 Sulfonylbenzene compounds as anti-inflammatory/analgesic agents |
| 03/28/2001 | EP1086085A1 INHIBITORS OF p38 |
| 03/28/2001 | EP1085894A1 Beta 3-adrenergic receptor agonists |
| 03/28/2001 | EP1085889A2 Novel therapeutic agents that modulate endothelin receptors |
| 03/28/2001 | EP1085887A2 Novel angiotensin receptor modulators and their uses |
| 03/28/2001 | EP1085870A2 Multivalent agonists, partial agonists and antagonists of the gaba receptors |
| 03/28/2001 | EP1085868A1 H1-histamine receptor antagonists |
| 03/28/2001 | EP1085862A1 Method of treating an autoimmune disorder |
| 03/28/2001 | EP1085847A2 Novel therapeutic agents that modulate estrogen receptors |
| 03/28/2001 | EP1085816A1 Dietary supplement derived from fermented milks for the prevention of osteoporosis |
| 03/27/2001 | US6207852 Smooth muscle spasmolytic agents, compositions and methods of use thereof |
| 03/27/2001 | US6207687 Substituted imidazoles having cytokine inhibitory activity |
| 03/22/2001 | WO2001019977A1 Embryonic or stem-like cell lines produced by cross species nuclear transplantation and methods for enhancing embryonic development by genetic alteration of donor cells or by tissue culture conditions |
| 03/22/2001 | WO2001019973A2 Nicotinic acetylcholine receptor: alpha10 subunit |
| 03/22/2001 | WO2001019966A2 Isolation of muscle-derived stem cells and uses therefor |
| 03/22/2001 | WO2001019860A2 Proteins associated with cell differentiation |
| 03/22/2001 | WO2001019855A2 Pharmaceutical compositions and methods of using secreted frizzled related protein |
| 03/22/2001 | WO2001019850A2 Nrage nucleic acids and polypeptides and uses thereof |
| 03/22/2001 | WO2001019819A2 Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment |
| 03/22/2001 | WO2001019817A2 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
| 03/22/2001 | WO2001019816A1 Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases |
| 03/22/2001 | WO2001019808A1 Chemical compounds and compositions and their use as cathepsin s inhibitors |
| 03/22/2001 | WO2001019796A1 Compounds and pharmaceutical compositions as cathepsin s inhibitors |
| 03/22/2001 | WO2001019379A2 Methods for treating muscular dystrophy with bone marrow cells |
| 03/22/2001 | WO2001019361A2 Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate |
| 03/22/2001 | WO2001019320A2 Phospholipid prodrugs of anti-proliferative drugs |
| 03/22/2001 | WO2001019182A1 Nuclear transfer with selected donor cells |
| 03/22/2001 | WO2000059899A8 Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them |
| 03/22/2001 | WO2000055155A3 Heterocyclic compounds as adenosine deaminase inhibitors |
| 03/22/2001 | WO2000040612A9 Insulin-like growth factor (igf) i mutant variants |